1416970-54-1

Basic information

• Product Name: 4-(4-(3-(2-(1-methylethoxy)phenoxy)propyl)piperazin-1-yl)-1-(phenylsulphonyl)-1H-indole
• Synonyms: 4-(4-(3-(2-(1-methylethoxy)phenoxy)propyl)piperazin-1-yl)-1-(phenylsulphonyl)-1H-indole
• CAS NO: 1416970-54-1
• Molecular Weight: 533.692
• Mol File: 1416970-54-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-(3-(2-(1-methylethoxy)phenoxy)propyl)piperazin-1-yl)-1-(phenylsulphonyl)-1H-indole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(3-(2-(1-methylethoxy)phenoxy)propyl)piperazin-1-yl)-1-(phenylsulphonyl)-1H-indole(1416970-54-1)
• EPA Substance Registry System: 4-(4-(3-(2-(1-methylethoxy)phenoxy)propyl)piperazin-1-yl)-1-(phenylsulphonyl)-1H-indole(1416970-54-1)

Safety Data

• Hazardous Substances Data: 1416970-54-1(Hazardous Substances Data)

Upstream product

• 117022-42-1 1-(3-chloropropoxy)-2-(1-methylethoxy)benzene 
• 393508-48-0 4-(1-benzenesulfonyl-1H-indol-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 98-09-9 benzenesulfonyl chloride 
• 252978-89-5 4-(1H-indol-4-yl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia

We describe a novel class of designed multiple ligands (DMLs) combining serotonin 5-HT6 receptor (5-HT6R) antagonism with dopamine D2 receptor (D2R) partial agonism. Prototype hybrid molecules were designed usin

INDOLEAMINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES

Indoleamine derivatives of formula (IA), wherein R1 represents benzyl unsubstituted or substituted with halogen atom, -OH, or C1-C3-alkyl; phenylsulphonyl unsubstituted or substituted in the phenyl ring with halogen atom, -OH or C1-C3-alkyl; G1 represents phenoxyalkyl, heteroaryloxyalkyl- or heterocyclyloxyalkyl-piperazine moiety; and pharmaceutically acceptable salts and solvates thereof. The compounds may be useful for the treatment and/or prevention of the central nervous system disorders.